New services complement existing cloud services for life sciences; Berg Pharma is an early client
BT, the global telecom company, has had a dedicated life sciences business unit for several years, has announced an alliance with Acclerys (San Diego), a provider of software tools and services for modelling and data management in industrial R&D, to provide the latter’s software in an integrated manner with BT’s communications and data management, which include BT’s On Demand Compute service (cloud services), BT Assure (security) and BT Connect (enabling communication among private, public and hybrid clouds). The initial rollout focuses on Accelerys’ Pipeline Pilot and related tools, which enable “in silico” drug development with collaboration among researchers and large database sources such as candidate drug libraries. “The communications and data-management services a pharma R&D organization uses can be a factor in time to market and cost of drug development,” says Yury Rozenman, head of marketing for BT Global Commerce. “At the same time, we’re building a range of services that can follow a drug from R&D to manufacturing to commercialization.”
A first client of BT for Life Sciences R&D is Berg Pharma (Boston), an integrated pharmaceutical developer that will integrate its proprietary Interrogative Biology platform, which the company uses to develop drug candidates. Berg intends to provide this platform to pharma partners via BT cloud services as well.
Rozenman points to BT’s services to the National Health Service, where communications involving patient healthcare records are combined with NHS’ reimbursement and compliance practices, as a model for how electronic health records (EHRs) in the US might connect with compliance, outcomes research and related issues affecting pharma businesses, but adds that many regulatory requirements remain to be worked out. BT can perform anonymization for NHS data, but isn’t fully equipped for HIPAA privacy rules in the US as yet.
In the meantime, the pharma industry continues to get more comfortable with cloud-based IT and communications services. Rozenman says that not only does BT provide multiple levels of communications security through its services, but it also is able to incorporate GxP standards (such as 21 CFR Part 11, which applies to electronic signatures on documents) to meet FDA requirements. The company’s US center of excellence is in Princeton, NJ.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.